JPRN-UMIN000001223Completed未知
A study to evaluate the efficacy of Rosuvastatin for patients with coronary plaque utilizing aggressive lipid lowering treatment - APOLLO
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Kokura Memorial Hospital
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) Patients with familial hypercholesterolemia (2) Patients who took lipid lowering agent within 1 month before the study . (3) Patients who have undergone PCI/CABG in separate sites of coronary arteries. (4) Patients with history of unstable angina or ischemic syndrome. (5) Patients with concomitant cardiac failure and patients who have lowered cardiac functions. (6) Patients receiving insulin treatment (7) Patients receiving cyclosporine (8) Patients with hepatic function disorder (AST/ALT>=100 IU/L) (9) Patients with renal function disorder (serum creatinine >= 1.5 mg/dL) (10) Patients with serum CK >= 500 IU/L (11) Pregnant women and women suspected of being pregnant (12) Patients with hypothyroidism, hereditary muscular diseases (muscular dystrophy, etc.) or familial history of these diseases. Patients with history of drug-related muscular disorder (13) Patients with drug abuse or alcoholism (14) Patients with serious complication (15) Patients who are ineligible at physicians' discretion
Investigators
Similar Trials
Recruiting
Phase 2
Rosuvastatin in patients with moderate brain traumaModerate traumatic brain injury.Diffuse traumatic brain injuryS06.2IRCT20230627058603N2Esfahan University of Medical Sciences200
Completed
Not Applicable
A Study To verify the efficacy of ROsuvastatin 2.5 mg as an aggressive lipid lowering therapy for hypercholesterolemia-1HypercholesterolemiaJPRN-UMIN000000812Graduate Scholl of Medicine, the University of Tokyo100
Completed
Not Applicable
A Study To verify the efficacy of ROsuvastatin 5 mg as an aggressive lipid lowering therapy for hypercholesterolemia (No.2)hypercholesterolemiaJPRN-UMIN000000912Graduate School of Medicine, the University of Tokyo900
Completed
Phase 3
Evaluation of the effects of Rosuvastatin in the treatment of patients with deep vein thrombosis(DVT)IRCT20150621022852N4Shahid Beheshti University of Medical Sciences50
Recruiting
Phase 3
A clinical trial to investigate the efficiency of rosuvastatin in acute cardiomyopathy induced anthracyclineCardiomyopathyIRCT2016121213090N3Vice chancellor for research of Mazandaran University of Medical Sciences80